Hawkeye Bio

Hawkeye Bio is a biotechnology company developing advanced biosensor technologies for the early detection and monitoring of disease. By integrating innovations in materials science, nanotechnology, and molecular diagnostics, Hawkeye Bio is producing highly sensitive diagnostic tests capable of detecting early biological signals associated with cancer and inflammatory disorders.

Hawkeye Bio, founded in 2019 and privately held, is focused on  the early detection of cancer, neurodegenerative disease and inflammatory conditions. The company’s lead program is in Lung Cancer (ProLung). Hawkeye Bio is based in Los Angeles and Ireland.

Its flagship technology includes graphene‑based biosensors for biomarker detection, which underpin their lung cancer diagnostics capabilities.